GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Global Blood Therapeutics (GBT) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 11:40 a.m. Eastern Time. The presentation will focus on the company's advancements in treating sickle cell disease (SCD) with products like Oxbryta (voxelotor) and ongoing pipeline projects, including inclacumab and GBT021601.

Investors can access the live webcast via GBT’s website, with a replay available for one month post-event.

Positive

• Participation in a significant healthcare conference enhances visibility and investor engagement.
• Leading the market with Oxbryta, the first FDA-approved treatment targeting SCD.
• Ongoing pipeline development signals commitment to advancing treatments for SCD.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual presentation at the 39^th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 11:40 a.m. Eastern Time.

The presentation and Q&A session will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601, the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:
Steven Immergut (investors and media)
650-410-3258
simmergut@gbt.com

Courtney Roberts (investors)
650-351-7881
croberts@gbt.com

FAQ

When will GBT present at the J.P. Morgan Healthcare Conference?

GBT will present on January 12, 2021, at 11:40 a.m. Eastern Time.

How can I access the GBT conference presentation?

The presentation will be available live on GBT's website, with a replay accessible for one month after the event.

What products does GBT focus on for sickle cell disease?

GBT focuses on Oxbryta (voxelotor) and is developing inclacumab and GBT021601 for SCD.